

February 02, 2023

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Subject: Press Release for Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2022

Dear Sir/ Madam,

Please find enclosed herewith the Press Release for the Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2022.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited

Rajat Kalra
Company Secretary and Legal Head

Encl.: As above

Dr. Lal PathLabs Limited records revenue of Rs 489 Cr in Q3 FY 2022-23

New Delhi, India, February 2, 2023 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended December 31, 2022.

Consolidated Performance Highlights: Q3 FY 2022-23 vs Q3 FY 2021-22

- Non-Covid Revenue increased by 9.1% in Q3 FY23 to Rs. 478 Cr vs Rs 438 Cr in Q3 FY22
- Total Revenue declined by 1.5% in Q3 FY23 to Rs. 489 Cr vs Rs 497 Cr in Q3 FY22
- Covid and Allied contributed 2% to Revenue in Q3 FY23, 12% in Q3 FY22
- Normalised EBITDA (after adjustment for stock based compensation, CSR) for Q3 FY23 is at Rs. 122 Cr (margins 24.9%) Vs Rs 119 Cr in the same quarter last year
- Normalised PBT* at Rs 89 Cr, margins 18.2% vs Rs 90 Cr. in Q3 last year
- Normalised PAT* at Rs 66 Cr, margins 13.5% vs Rs 66 Cr. in Q3 last year

Financial Overview (Consolidated) in Rs Cr

Particulars	Q3			YTD Dec		
	FY23	FY22	Gr %	FY23	FY22	Gr %
Revenue	489	497	-1.5%	1526	1602	-4.7%
<i>Non Covid</i>	478	438	9.1%	1474	1272	15.9%
<i>Covid & Allied</i>	11	59	-80.4%	52	330	-84.2%
Expenditure	376	388	-2.9%	1152	1162	-0.9%
EBITDA	113	109	3.4%	374	440	-14.9%
<i>EBITDA Margins</i>	23.1%	22.0%		24.5%	27.4%	
RSU & CSR cost	9	9		23	30	
Normalised EBITDA	122	119	2.8%	397	470	-15.4%
<i>EBITDA Margins</i>	24.9%	23.9%		26.0%	29.3%	
Net other Income/(Interest)	1	3		-1	22	
Depreciation Cost	25	23		75	62	
Notional Depreciation-SDIPL	12	8		37	8	
PBT	76	82	-6.2%	261	391	-33.4%
<i>Margins</i>	15.6%	16.4%		17.1%	24.4%	
PAT	54	58	-7.9%	184	288	-36.1%
<i>Margins</i>	11.0%	11.7%		12.1%	18.0%	
EPS	6.4	6.9	-7.9%	22.0	34.3	-35.8%
Normalised PBT*	89	90	-0.8%	298	399	-25.5%
<i>Margins</i>	18.2%	18.0%		19.5%	24.9%	
Normalised PAT*	66	66	-0.3%	221	296	-25.3%
<i>Margins</i>	13.5%	13.3%		14.5%	18.5%	

*Normalised PBT and PAT are excluding notional depreciation.



About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2022 the company has 277 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata & Bangalore), 4,731 Patient Service Centers (PSCs) and 10,599 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Goel
Group Chief Financial Officer
Dr. Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Rakshit Tewari/Gargi Mukherjee
Adfactors PR

+91 9935551036/+91 9650944756
rakshit.tewari@adfactorspr.com
gargi.mukherjee@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.